1-(tert-butoxycarbonyl)-5-[2-(4-phenyl-5-trifluormethyl-2-thienyl)ethyl]indoline | 957204-41-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(tert-butoxycarbonyl)-5-[2-(4-phenyl-5-trifluormethyl-2-thienyl)ethyl]indoline
• 英文别名: 1-(Tert-butoxycarbonyl)-5-[2-[4-phenyl-5-(trifluoromethyl)-2-thienyl]ethyl]indoline；tert-butyl 5-[2-[4-phenyl-5-(trifluoromethyl)thiophen-2-yl]ethyl]-2,3-dihydroindole-1-carboxylate
• CAS: 957204-41-0
• 化学式: C₂₆H₂₆F₃NO₂S
• 分子量: 473.559
• InChiKey: DBTNNPZKOSZVGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  57.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-(tert-butoxycarbonyl)-5-[2-(4-phenyl-5-trifluormethyl-2-thienyl)ethyl]indoline 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 5-[2-(4-phenyl-5-trifluormethyl-2-thienyl)ethyl]indoline hydrochloride
  参考文献：
  名称：

  EP2017263

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(tert-butoxycarbonyl)-5-[(E)-2-(4-phenyl-5-trifluormethyl-2-thienyl)ethenyl]indoline 在 5%-palladium/activated carbon 氢气 作用下， 以 乙酸乙酯 为溶剂， 反应 3.0h， 生成 1-(tert-butoxycarbonyl)-5-[2-(4-phenyl-5-trifluormethyl-2-thienyl)ethyl]indoline
  参考文献：
  名称：

  EP2017263

  摘要：

  公开号：

文献信息

• HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE
  申请人：Machinaga Nobuo

  公开号：US20090324581A1

  公开（公告）日：2009-12-31

  To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH 2 —; R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G 1 -, (2) -G 2 -N(R 2 )-G 3 -, and (3) a group represented by formula 2, wherein each of Z 1 and Z 2 represents a hydrogen atom or a C 1 -C 6 alkyl group, Z 3 represents a hydrogen or the like, Q represents —CH 2 —O— or the like, and Y represents a group represented by formula 3, a salt thereof, or a solvate thereof.

  提供一种新型化合物，具有S1P受体激动活性，表现出优异的免疫抑制效果，产生较少的不良副作用，并可口服。本发明提供一种由通式（I）表示的化合物（其中A是单键，-O-或-CH2-；R1表示氢原子或C1-C6烷基基团，V表示从以下组（1）至（3）中选择的任一组：（1）-G1-，（2）-G2-N（R2）-G3-，以及（3）由式2表示的组，其中Z1和Z2分别表示氢原子或C1-C6烷基基团，Z3表示氢或类似物，Q表示-CH2-O-或类似物，Y表示由式3表示的基团，其盐或溶剂化物。
• DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE
  申请人：Merck & Co., Inc.

  公开号：EP1651231A2

  公开（公告）日：2006-05-03
• EP1651231A4
  申请人：——

  公开号：EP1651231A4

  公开（公告）日：2009-04-01
• [EN] DIPHENYL SUBSTITUTED CYCLOALKANES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE<br/>[FR] CYCLOALCANES DIPHENYL-SUBSTITUTES, COMPOSITIONS CONTENANT CES COMPOSES, ET PROCEDES D'UTILISATION
  申请人：MERCK & CO INC

  公开号：WO2005009951A2

  公开（公告）日：2005-02-03

  The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
• [EN] NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE PYRAZOLO[3,4-D]PYRIMIDINE
  申请人：ABBOTT LAB

  公开号：WO2011156698A2

  公开（公告）日：2011-12-15

  The present disclosure is directed to novel compounds of Formula (I), pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.